etoposide + paclitaxel + cisplatin

EP + TP-Hebei Tumor Hospital-lung cancer refers to the chemotherapy regimens EP (etoposide and cisplatin) and TP (paclitaxel and cisplatin) utilized in a clinical trial sponsored by Hebei Tumor Hospital. This pilot study investigated these platinum-based doublets as first-line treatment in aged patients with lung cancer, specifically evaluating their efficacy and safety when combined with zoledronic acid to assess impacts on bone mineral density and survival. Etoposide is a semisynthetic derivative of podophyllotoxin that acts as a topoisomerase II inhibitor, preventing DNA ligation and causing double-strand breaks. Paclitaxel is a taxane that stabilizes microtubules, inhibiting their depolymerization and arresting the cell cycle. Cisplatin is a platinum-based antineoplastic agent that forms covalent adducts with DNA, leading to inter- and intra-strand cross-links that trigger apoptosis in rapidly dividing cancer cells.

Other names

etoposide + cisplatinpaclitaxel + cisplatinVP-16 + DDPPTX + DDP